A second pair of trained eyes,
before the treatment plan is signed.
NgsAdvisory is a physician-led molecular second-opinion practice. We translate next-generation sequencing into a tier-classified, resistance-mapped, signed report, addressed to the oncologist who has to make the call.
The treating physician retains decision authority. We hand them the evidence (tier-classified, sequenced, resistance-mapped) before they sign the plan.
Built around one signature.
The practice is small by design. Every report carries a personal sign-off, the medicine of accountability, not of throughput.
Plate · 014 / Portrait
Prof. İbrahim Yıldız, MD, is the physician behind every NGS Advisory report. He is a Professor of Medical Oncology with more than 20 years at the intersection of precision oncology and clinical cancer care.
He trained in medicine and internal medicine at Istanbul University-Cerrahpaşa Faculty of Medicine, and in medical oncology at the Institute of Oncology, Istanbul University, two of Türkiye's oldest and most established medical institutions. He practices at Acıbadem Mehmet Ali Aydınlar University, part of one of the region's largest internationally accredited healthcare groups, and is a member of ESMO and ASCO.
His work centers on precision medicine: next-generation sequencing and targeted therapy. With 130+ peer-reviewed publications, including, as corresponding author, comprehensive NGS-based genomic profiling in advanced sarcoma (Frontiers in Oncology, 2025), his expertise is grounded in published research, not interpretation alone. That research translates directly to practice: he routinely re-reads NGS panels (FoundationOne, Tempus, Guardant, Caris and others) for international and second-opinion patients, turning raw variant data into a clear, guideline-anchored plan their treating oncologist can act on.
Every NGS Advisory report is personally reviewed and signed by Prof. Yıldız: decision support for the treating physician.
Why a second opinion, and why molecular.
at the heart of NGS.
Sequencing has become almost trivial to order. The bottleneck has moved upstream: a 60-page molecular report arrives on a Friday afternoon, mid-clinic, with twenty-two variants of unknown significance and a six-line summary written by a system that has never met the patient.
NgsAdvisory is being built to be that reader. The practice does one thing: re-classify variants, surface what the algorithm misses, sequence the regimens by tier of evidence, and map the resistance pathway one move ahead. The output is a report a physician can sign their own name underneath.
We do not treat. We do not prescribe. We do not replace the treating oncologist or the tumor board. We are the second pair of trained eyes a busy clinic does not have the hours to staff in-house, and that, in molecular oncology, is the difference between a panel and a plan.
Two decades of medical oncology, behind one signature.
NgsAdvisory is a new practice. The numbers below are Prof. İbrahim Yıldız’s own, the experience he is bringing to the reading room.
What we read against.
Every recommendation in our reports is anchored to a public, peer-reviewed standard. We don’t invent classifications and we don’t borrow from the panel manufacturer. The reading is the work.
Send a panel. Receive a physician-read second opinion.
The practice is open to its first referring oncologists. If you have a sequencing panel that needs a second pair of trained eyes, we read in the order received, target turnaround 72 hours, signed by Prof. İbrahim Yıldız.